Shanghai Henlius Biotech has formed a strategic collaboration with Sandoz to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars globally, excluding China. The partnership builds on their 2025 oncology biosimilars deal and includes upfront and milestone payments totaling up to $322 million, with Henlius expecting invoiced revenue of $100.5 million in 2026. This collaboration leverages Henlius' biologics development and manufacturing capabilities and Sandoz's global commercialization network, aiming to accelerate global market access for these biosimilars. Key products include biosimilars for cetuximab, evolocumab, and belimumab, with most still in early development stages.
X-energy (XE) is advancing as a nuclear technology platform with proprietary TRISO-X fuel and reactor services, aiming for $1.8 billion in annual revenue by 2032 and over 42% gross margins. Its pipeline includes major companies such as Dow, Amazon, a...
SmartCentres Real Estate Investment Trust (REIT), one of Canada's largest with nearly C$11 billion in properties, is trading close to its net asset value (NAV) at a fair value of C$35 per unit. Its adjusted funds from operations (AFFO) comfortably co...
Nvidia's latest AI chips deliver significantly higher performance than China's best, Huawei's Ascend 910C, which is less than half as powerful as Nvidia's three-year-old H200 chip. Nvidia has since advanced through multiple chip generations, with its...
Antero Resources is expected to benefit this winter from increasing natural gas demand driven by disruptions in Iranian supply, growth in data center usage, and expanding export capacity in North America. Its strategic location near Greater Philadelp...
Japan's government has selected a joint venture between Rakuten and AST SpaceMobile for its J-LEO satellite initiative, providing up to $1 billion in funding and pushing the program's value toward $2 billion with private matching. AST SpaceMobile is ...
